Siemens: the test for quantity of antibodies to COVID-19

2020: The announcement of the test from Siemens Healthineers defining quantity of antibodies to COVID-19

At the beginning of August, 2020 released Siemens Healthineers the first-ever test defining quantity of antibodies to COVID-19, SARS-CoV-2 IgG (COV2G). The test for COV2G not only yields positive or negative result, but also reports the numerical result expressed as index value which helps clinical physicians to estimate the level of antibodies of IgG in a blood sample of the patient.

It is already the fifth Siemens Healthineers test for antibodies to COVID-19 which got the emergency approval regulatory bodies since the beginning of a pandemic. Using a new technique researchers hope to study dynamics of the immune answer of people after contact with a coronavirus eventually. While the test for the general antibodies of SARS-CoV-2 reveals antibodies of IgM and IgG which are present both at early, and at later stage of the immune answer, the semi-quantitative test for COV2G antibodies specifically reveals antibodies of IgG which remain and are a basis for a long-term research of immunity. The combination of these tests gives complete idea of the serological status of the patient.

Emergence of the test from Siemens Healthineers defining quantity of antibodies to a coronavirus

The test got approval from regulatory bodies of the USA and the European Union. According to Siemens Healthineers, the test for IgG antibodies to SARS-CoV-2 provides to 100% sensitivity and 99.9% specificity that is very important for exact determination of the adaptive immune answer.

High-precision results of tests for antibodies can be used as the addition to the PTsR tests for simplification of clinical assessment. Besides, they allow to estimate the previous contact with a virus, to identify donors of plasma among recovering and also can be applied to the epidemiological purposes, including establishment of prevalence of a disease among the population, and to efficiency evaluation of candidate vaccines.^[1]

Notes